‘Molecular glue’ from this San Diego startup makes cancer self-destruct: Clinical trial begins
This local biotech says it has found a way to trick cancer cells into destroying themselves with its molecular glue. Now it's putting that claim to the test. After attracting global attention from researchers and billions of dollars from Big Pharma, Neomorph announced that it has begun its first clinical trial. The molecular glue aims to treat a form of kidney cancer.